Intratumoral Immunotherapy Draws Renewed Attention but Does It Work? Kate Johnson

https://www.medscape.com/viewarticle/intratumoral-immunotherapy-draws-renewed-attention-does-it-2026a10012vx After years on the margins, intratumoral immunotherapy is drawing renewed attention following the FDA’s recent approval of vusolimogene oderparepvec (Tudriqev, Replimune), the second immunotherapy approved for intratumoral use. The drug is approved in combination with nivolumab to treat advanced melanoma that has progressed after an anti-PD-1-containing regimen.